Srihari Naidu, MD
Interventional Cardiology · Mineola, NYNPI 1306948302
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 59.4% of the total. Reporting peaked in 2022 at $95,169 and has fallen 81.4% since, to $17,687 in 2025. Among interventional cardiology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 247 payments — averaging $981.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$144K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$51K
- Chiesi USA, Inc.$33K
- AstraZeneca$3K
- ZOLL Circulation Inc$3K
- Abbott$2K
- plus $7K from 25 others
Across 16 payments — averaging $21,007 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$335K
- ZOLL Circulation Inc$900
What the payments were for
- Consulting fees$84,08335%
- Speaking & faculty fees$142,64559%
- Grants$1,2221%
- Travel & lodging$6,0472%
- Food & beverage$8,4803%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 94 | $144,084 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 20 | $51,073 |
| Chiesi USA, Inc. | 9 | $32,816 |
| AstraZeneca | 9 | $3,336 |
| ZOLL Circulation Inc | 5 | $2,757 |
| Abbott | 52 | $1,816 |
| Abiomed | 13 | $1,387 |
| Boston Scientific | 3 | $1,278 |
| Cordis US CORP. | 1 | $1,050 |
| Medical Device Business Services, Inc. | 2 | $544 |
| Philips North America LLC | 3 | $527 |
| Opsens Inc. | 3 | $318 |
| Biosense Webster, Inc. | 5 | $297 |
| W. L. Gore & Associates, Inc. | 1 | $290 |
| Stryker | 3 | $199 |
| GE HealthCare | 1 | $113 |
| Edwards Lifesciences | 1 | $107 |
| Baxter Healthcare | 3 | $96 |
| Amarin Pharma, Inc. | 4 | $71 |
| Novartis | 2 | $52 |
| Irhythm Technologies, Inc. | 2 | $43 |
| Mallinckrodt Hospital Products Inc. | 1 | $39 |
| Cardiva Medical, Inc. | 2 | $36 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Bardy Diagnostics, Inc. | 1 | $22 |
| Penumbra, Inc. | 1 | $21 |
| Terumo Medical Corporation | 1 | $21 |
| Recor Medical Inc | 1 | $19 |
| Pfizer | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| Biotronik Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$80,495
- LifeVest$51,000
- KENGREAL$32,759
- BRILINTA$2,811
- TherOx DS2 Console$2,664
- Catheter$2,664
- Downstream Cartridge$2,664
- GENERAL TACHY$1,222
- MYNX CONTROL$1,050
- Impella$1,033
- Carto 3$655
- (9525) Intracardiac Und$322
- OptoWire$291
- AMPLATZER Occluders$290
- Product in Development$290
- IGT D Serv Und$185
- ENSITE$165
- OptoMonitor$143
- CLOTTRIEVER BOLD CATHETER$136
- AMPLATZER PICCOLO$110
How this compares
$242,476 in reported general payments places this provider in the 95th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CamzyosMavacamten | 134 | $1,023,172 |
| EliquisApixaban | 50 | $72,881 |
| Disopyramide Phosphate | 54 | $10,367 |
| Metoprolol Succinate | 114 | $2,190 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 30 | $759 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 54 | $657 |
| Rosuvastatin Calcium | 47 | $601 |
| Valsartan | 11 | $503 |
| Furosemide | 34 | $321 |
| Atorvastatin Calcium | 33 | $243 |
| Amlodipine Besylate | 38 | $198 |
| Carvedilol | 19 | $155 |
| Hydrochlorothiazide | 49 | $140 |
| Spironolactone | 19 | $134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Camzyos | $144,084 | $1,023,172134 claims |
| PfizerEliquis | $15 | $72,88150 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in Mineola
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Evan ShlofmitzRoslyn$951K
- Mohamed Azeem LatibBronx$816K
- Yili HuangElmhurst$699K
- Ali HaiderAstoria$492K
- Sripal BangaloreNew York$482K
- Ajay KirtaneNew York$462K
- David CohenRoslyn$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.